• DaVita Inc. has released its first-quarter 2026 results, reporting revenue of US$3.42 billion and net income of US$197.53 million, with both basic and diluted earnings per share from continuing operations rising compared with a year earlier.
• The earnings update shows DaVita generating higher profit per share on relatively modest revenue growth, suggesting that recent operational changes are feeding through to improved efficiency.
• We’ll now examine how this stronger earnings and margin performance influences DaVita’s existing investment narrative built around cost efficiency and earnings growth.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

DaVita Investment Narrative Recap

To own DaVita, you need to believe that aging demographics and chronic kidney disease keep dialysis demand resilient, while efficiency gains support earnings growth despite reimbursement and volume pressures. The Q1 2026 update, with higher earnings per share on modest revenue growth, reinforces the cost efficiency part of this thesis in the near term. It does not materially change the key short term catalyst of margin improvement or the biggest risk around treatment volumes and patient mortality.

The earlier February 2026 update on Q4 and full year 2025 results showed revenue rising but net income and EPS declining year on year, underlining how fragile margins had been. Against that backdrop, the Q1 2026 rebound in earnings per share looks more like an early sign of operational improvements starting to stick, rather than a clear break from prior margin pressure, and it keeps the focus firmly on whether efficiency gains can offset reimbursement limits and volume headwinds.

Yet even with stronger recent margins, investors should be aware that persistent pressure on treatment volumes and missed treatments could still...

DaVita’s narrative projects $15.2 billion revenue and $914.0 million earnings by 2029. This requires 3.6% yearly revenue growth and about a $192 million earnings increase from $721.8 million today.

Uncover how DaVita's forecasts yield a $151.71 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming revenue of about US$15.3 billion and earnings of roughly US$803.0 million by 2029, and they focus heavily on the risk that persistent pressure on treatment volumes and missed treatments could weigh on growth. Compared with the more optimistic cost efficiency story reinforced by the latest Q1 numbers, this is a much more cautious view, and it shows how your own stance might shift as new results test both narratives over time.

Explore 2 other fair value estimates on DaVita - why the stock might be worth just $151.71!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.